Coherus BioSciences - CHRS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 102.77 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$9.37
▼ -0.24 (-2.50%)

This chart shows the closing price for CHRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Coherus BioSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHRS

Analyst Price Target is $19.00
▲ +102.77% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Coherus BioSciences in the last 3 months. The average price target is $19.00, with a high forecast of $30.00 and a low forecast of $7.00. The average price target represents a 102.77% upside from the last price of $9.37.

This chart shows the closing price for CHRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Coherus BioSciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/16/2022MizuhoBoost TargetBuy$25.00 ➝ $28.00Low
6/13/2022UBS GroupInitiated CoverageNeutral$7.00High
5/20/2022MizuhoLower TargetBuy$30.00 ➝ $25.00High
5/9/2022BarclaysLower Target$20.00 ➝ $15.00High
5/3/2022HC WainwrightReiterated RatingBuy$30.00Low
3/23/2022MizuhoReiterated RatingBuy$30.00High
3/7/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$20.00 ➝ $15.00Low
2/22/2022BarclaysLower Target$24.00 ➝ $20.00High
2/7/2022JPMorgan Chase & Co.Lower Target$23.00 ➝ $20.00High
11/9/2021HC WainwrightLower TargetBuy$36.00 ➝ $30.00High
10/6/2021HC WainwrightReiterated RatingBuy$36.00Low
8/6/2021Maxim GroupInitiated CoverageBuy$22.00Medium
7/23/2021HC WainwrightBoost TargetBuy$26.00 ➝ $36.00High
5/17/2021BarclaysLower TargetOverweight$28.00 ➝ $24.00High
5/13/2021HC WainwrightLower TargetBuy$29.00 ➝ $26.00Low
5/7/2021Maxim GroupInitiated CoverageBuy$22.00Low
5/7/2021HC WainwrightLower TargetBuy$28.00 ➝ $26.00High
2/25/2021CitigroupLower Target$30.00 ➝ $27.00High
2/25/2021HC WainwrightLower TargetBuy$33.00 ➝ $29.00High
11/19/2020MizuhoLower TargetBuy$35.00 ➝ $30.00Low
11/6/2020HC WainwrightLower TargetBuy$33.00 ➝ $32.00High
8/7/2020Maxim GroupInitiated CoverageBuy$27.00High
8/7/2020HC WainwrightBoost TargetBuy$30.00 ➝ $33.00Medium
7/16/2020Bank of AmericaInitiated CoverageNeutral$20.00Low
5/9/2020Maxim GroupInitiated CoverageBuy$27.00Medium
5/8/2020HC WainwrightReiterated RatingBuy$30.00High
4/17/2020SunTrust BanksInitiated CoverageBuy$26.00High
3/5/2020Credit Suisse GroupReiterated RatingBuy$36.00Low
2/29/2020Maxim GroupReiterated RatingBuy$27.00High
2/28/2020HC WainwrightBoost TargetBuy$29.00 ➝ $30.00High
2/6/2020JPMorgan Chase & Co.Boost TargetOverweight$33.00 ➝ $35.00Medium
2/4/2020MizuhoReiterated RatingBuy$43.00High
11/27/2019MizuhoInitiated CoverageBuy$43.00Medium
11/25/2019HC WainwrightReiterated RatingBuy$29.00Low
11/8/2019Credit Suisse GroupReiterated RatingBuy$36.00Low
9/29/2019MizuhoSet TargetBuy$43.00Medium
8/13/2019MizuhoInitiated CoverageBuy ➝ Buy$43.00Medium
8/12/2019BarclaysSet TargetBuy$31.00Low
8/2/2019Maxim GroupReiterated RatingBuy ➝ Buy$25.00 ➝ $27.00High
8/2/2019HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $29.00High
7/10/2019Maxim GroupReiterated RatingBuy$25.00Low
6/21/2019BarclaysSet TargetBuy$30.00Low
6/19/2019Robert W. BairdSet TargetBuy$28.00Low
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$30.00Medium
5/10/2019Maxim GroupSet TargetBuy$25.00High
5/7/2019HC WainwrightInitiated CoverageBuy ➝ Buy$28.00High
4/10/2019Robert W. BairdSet TargetBuy$28.00Low
4/8/2019Maxim GroupReiterated RatingBuy$25.00High
3/7/2019Credit Suisse GroupSet TargetBuy$25.00Medium
11/5/2018HC WainwrightSet TargetBuy$28.00High
11/2/2018CowenReiterated RatingBuy$45.00High
9/26/2018HC WainwrightSet TargetBuy$28.00High
9/25/2018Maxim GroupReiterated RatingBuy$25.00Medium
8/28/2018HC WainwrightInitiated CoverageBuy ➝ Buy$28.00High
5/11/2018Maxim GroupBoost TargetBuy ➝ Buy$18.00 ➝ $22.00High
5/3/2018Maxim GroupSet TargetBuy$18.00Medium
3/9/2018CitigroupBoost TargetBuy ➝ Buy$23.00 ➝ $25.00Low
3/9/2018Maxim GroupReiterated RatingBuy ➝ Buy$20.00 ➝ $15.00High
11/7/2017CitigroupReiterated RatingBuy$23.00N/A
(Data available from 10/4/2017 forward)

News Sentiment Rating

1.62 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
3/7/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/6/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
6/5/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/5/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/4/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/3/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.
Coherus BioSciences logo
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $9.37
Low: $9.14
High: $9.86

50 Day Range

MA: $10.74
Low: $7.43
High: $13.87

52 Week Range

Now: $9.37
Low: $5.60
High: $19.32

Volume

863,203 shs

Average Volume

1,012,177 shs

Market Capitalization

$728.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Coherus BioSciences?

The following equities research analysts have issued research reports on Coherus BioSciences in the last year: Barclays PLC, HC Wainwright, JPMorgan Chase & Co., Mizuho, StockNews.com, and UBS Group AG.
View the latest analyst ratings for CHRS.

What is the current price target for Coherus BioSciences?

5 Wall Street analysts have set twelve-month price targets for Coherus BioSciences in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 102.8%. HC Wainwright has the highest price target set, predicting CHRS will reach $30.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $7.00 for Coherus BioSciences in the next year.
View the latest price targets for CHRS.

What is the current consensus analyst rating for Coherus BioSciences?

Coherus BioSciences currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CHRS will outperform the market and that investors should add to their positions of Coherus BioSciences.
View the latest ratings for CHRS.

What other companies compete with Coherus BioSciences?

How do I contact Coherus BioSciences' investor relations team?

Coherus BioSciences' physical mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company's listed phone number is (650) 649-3530 and its investor relations email address is [email protected] The official website for Coherus BioSciences is www.coherus.com. Learn More about contacing Coherus BioSciences investor relations.